Molecular therapies for viral hepatitis

Chandan Guha, Shalin J. Shah, Siddhartha S. Ghosh, Sung W. Lee, Namita Roy-Chowdhury, Jayanta Roy-Chowdhury

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Current treatment modalities available for hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are not efficient. The enormous disease burden caused by these two infections makes the development of novel therapies critical. For HCV, the development of an effective vaccine is urgent in view of the escalating number of infected individuals. Molecular therapies for HBV and HCV infection can be directed at reducing viral load by interfering with the life cycle of the viruses or at generating immune response against viral epitopes. The antiviral approaches consist of the delivery or expression of antisense RNAs, ribozymes or dominant negative proteins. Viral biology can be interrupted by attacking various potential targets within the two viruses. DNA-based vaccination strategies are being explored for both prevention and treatment of these diseases. Both non-viral and recombinant viral vectors are being developed for safe, effective and long-term gene transfer to the liver. Although no 'ideal' vector is available at this time, the ingenuity of numerous investigators is leading to the improvement of the vector systems, promising successful application of gene therapy to the prevention and treatment of viral hepatitis in the foreseeable future.

Original languageEnglish (US)
Pages (from-to)81-91
Number of pages11
JournalBioDrugs
Volume17
Issue number2
DOIs
StatePublished - 2003

Fingerprint

Hepatitis
Hepacivirus
Virus Diseases
Hepatitis B virus
Viruses
Therapeutics
Antisense RNA
Catalytic RNA
Life Cycle Stages
Viral Load
Genetic Therapy
Antiviral Agents
Epitopes
Vaccination
Vaccines
Research Personnel
Liver
DNA
Infection
Genes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Immunology and Allergy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Guha, C., Shah, S. J., Ghosh, S. S., Lee, S. W., Roy-Chowdhury, N., & Roy-Chowdhury, J. (2003). Molecular therapies for viral hepatitis. BioDrugs, 17(2), 81-91. https://doi.org/10.2165/00063030-200317020-00001

Molecular therapies for viral hepatitis. / Guha, Chandan; Shah, Shalin J.; Ghosh, Siddhartha S.; Lee, Sung W.; Roy-Chowdhury, Namita; Roy-Chowdhury, Jayanta.

In: BioDrugs, Vol. 17, No. 2, 2003, p. 81-91.

Research output: Contribution to journalArticle

Guha, C, Shah, SJ, Ghosh, SS, Lee, SW, Roy-Chowdhury, N & Roy-Chowdhury, J 2003, 'Molecular therapies for viral hepatitis', BioDrugs, vol. 17, no. 2, pp. 81-91. https://doi.org/10.2165/00063030-200317020-00001
Guha, Chandan ; Shah, Shalin J. ; Ghosh, Siddhartha S. ; Lee, Sung W. ; Roy-Chowdhury, Namita ; Roy-Chowdhury, Jayanta. / Molecular therapies for viral hepatitis. In: BioDrugs. 2003 ; Vol. 17, No. 2. pp. 81-91.
@article{fda134d3052146408b041965e8b5deaa,
title = "Molecular therapies for viral hepatitis",
abstract = "Current treatment modalities available for hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are not efficient. The enormous disease burden caused by these two infections makes the development of novel therapies critical. For HCV, the development of an effective vaccine is urgent in view of the escalating number of infected individuals. Molecular therapies for HBV and HCV infection can be directed at reducing viral load by interfering with the life cycle of the viruses or at generating immune response against viral epitopes. The antiviral approaches consist of the delivery or expression of antisense RNAs, ribozymes or dominant negative proteins. Viral biology can be interrupted by attacking various potential targets within the two viruses. DNA-based vaccination strategies are being explored for both prevention and treatment of these diseases. Both non-viral and recombinant viral vectors are being developed for safe, effective and long-term gene transfer to the liver. Although no 'ideal' vector is available at this time, the ingenuity of numerous investigators is leading to the improvement of the vector systems, promising successful application of gene therapy to the prevention and treatment of viral hepatitis in the foreseeable future.",
author = "Chandan Guha and Shah, {Shalin J.} and Ghosh, {Siddhartha S.} and Lee, {Sung W.} and Namita Roy-Chowdhury and Jayanta Roy-Chowdhury",
year = "2003",
doi = "10.2165/00063030-200317020-00001",
language = "English (US)",
volume = "17",
pages = "81--91",
journal = "BioDrugs",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Molecular therapies for viral hepatitis

AU - Guha, Chandan

AU - Shah, Shalin J.

AU - Ghosh, Siddhartha S.

AU - Lee, Sung W.

AU - Roy-Chowdhury, Namita

AU - Roy-Chowdhury, Jayanta

PY - 2003

Y1 - 2003

N2 - Current treatment modalities available for hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are not efficient. The enormous disease burden caused by these two infections makes the development of novel therapies critical. For HCV, the development of an effective vaccine is urgent in view of the escalating number of infected individuals. Molecular therapies for HBV and HCV infection can be directed at reducing viral load by interfering with the life cycle of the viruses or at generating immune response against viral epitopes. The antiviral approaches consist of the delivery or expression of antisense RNAs, ribozymes or dominant negative proteins. Viral biology can be interrupted by attacking various potential targets within the two viruses. DNA-based vaccination strategies are being explored for both prevention and treatment of these diseases. Both non-viral and recombinant viral vectors are being developed for safe, effective and long-term gene transfer to the liver. Although no 'ideal' vector is available at this time, the ingenuity of numerous investigators is leading to the improvement of the vector systems, promising successful application of gene therapy to the prevention and treatment of viral hepatitis in the foreseeable future.

AB - Current treatment modalities available for hepatitis B virus (HBV) or hepatitis C virus (HCV) infections are not efficient. The enormous disease burden caused by these two infections makes the development of novel therapies critical. For HCV, the development of an effective vaccine is urgent in view of the escalating number of infected individuals. Molecular therapies for HBV and HCV infection can be directed at reducing viral load by interfering with the life cycle of the viruses or at generating immune response against viral epitopes. The antiviral approaches consist of the delivery or expression of antisense RNAs, ribozymes or dominant negative proteins. Viral biology can be interrupted by attacking various potential targets within the two viruses. DNA-based vaccination strategies are being explored for both prevention and treatment of these diseases. Both non-viral and recombinant viral vectors are being developed for safe, effective and long-term gene transfer to the liver. Although no 'ideal' vector is available at this time, the ingenuity of numerous investigators is leading to the improvement of the vector systems, promising successful application of gene therapy to the prevention and treatment of viral hepatitis in the foreseeable future.

UR - http://www.scopus.com/inward/record.url?scp=0037258795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037258795&partnerID=8YFLogxK

U2 - 10.2165/00063030-200317020-00001

DO - 10.2165/00063030-200317020-00001

M3 - Article

C2 - 12641487

AN - SCOPUS:0037258795

VL - 17

SP - 81

EP - 91

JO - BioDrugs

JF - BioDrugs

SN - 1173-8804

IS - 2

ER -